Literature DB >> 2388657

The electrophysiologic profile of Dejerine-Sottas disease (HMSN III).

T J Benstead1, N L Kuntz, R G Miller, J R Daube.   

Abstract

Electrophysiologic studies in 11 patients with Dejerine-Sottas disease (hereditary motor and sensory neuropathy type III, HMSN III) showed median and ulnar motor nerve conduction velocities less than 6 m/sec in all but 1 patient. Marked temporal dispersion without conduction block was present in all patients. Uniform slowing in adjacent motor nerves was consistent with other studies of inherited neuropathies, although marked temporal dispersion may make HMSN III more difficult to distinguish from acquired neuropathies than other hereditary conditions. The electrophysiologic features of HMSN III patients were significantly different from a series of patients with other hereditary neuropathies chosen because of very slow nerve conduction velocity.

Entities:  

Mesh:

Year:  1990        PMID: 2388657     DOI: 10.1002/mus.880130705

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  4 in total

1.  Homozygous hypertrophic hereditary motor and sensory neuropathies.

Authors:  A Sghirlanzoni; D Pareyson; R Marazzi; G Cavaletti; E Bellone; P Mandich; M R Balestrini; D Riva
Journal:  Ital J Neurol Sci       Date:  1994-02

2.  Chronic inflammatory demyelinating polyneuropathy in childhood: clinical and electrophysiological features.

Authors:  A Uncini; E Parano; D J Lange; D C De Vivo; R E Lovelace
Journal:  Childs Nerv Syst       Date:  1991-08       Impact factor: 1.475

Review 3.  Dejerine-Sottas syndrome grown to maturity: overview of genetic and morphological heterogeneity and follow-up of 25 patients.

Authors:  Anneke Gabreëls-Festen
Journal:  J Anat       Date:  2002-04       Impact factor: 2.610

4.  A novel recessive Nefl mutation causes a severe, early-onset axonal neuropathy.

Authors:  Sabrina W Yum; Junxian Zhang; Katie Mo; Jian Li; Steven S Scherer
Journal:  Ann Neurol       Date:  2009-12       Impact factor: 10.422

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.